Baylor College of Medicine

Final Call for 2023 Biocodex Microbiota Foundation $50,000 U.S. Research Grant Applications

Retrieved on: 
Thursday, September 14, 2023
Human, University, Stanford University, Autism spectrum, DSM-IV codes, Research, Microbiota, Texas Children's Hospital, ASD, Michigan State University, Baylor College of Medicine, Hospital, University of California, Los Angeles, UCLA, Health, Disease, Medical device, Nursing, Pharmaceutical industry

BEDMINSTER, N.J., Sept. 14, 2023 /PRNewswire-PRWeb/ -- With the submission deadline approaching, the Biocodex Microbiota Foundation is announcing its last call for applications for their $50,000 research grant. The application can be downloaded online and is due by October 1, 2023.

Key Points: 
  • BEDMINSTER, N.J., Sept. 14, 2023 /PRNewswire-PRWeb/ -- With the submission deadline approaching, the Biocodex Microbiota Foundation is announcing its last call for applications for their $50,000 research grant.
  • Other previous Biocodex Microbiota Foundation $50,000 grant recipients include:
    The Biocodex Microbiota Foundation's annual call for grant applications is part of a multi-year research initiative to understand the interaction between microbiota and different pathologies.
  • Late or incomplete applications, or those that don't meet the criteria of the grant program or research topic, will not be considered.
  • To learn more information about Biocodex Microbiota Foundation and the 2023 US grant program, visit here .

Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder

Retrieved on: 
Tuesday, September 12, 2023
Baylor University, Neuroscience, Jennifer White-Johnson, Doctor of Philosophy, Depression, Discovery, MD, Mount, Psychiatry, Behavioural sciences, Baylor College of Medicine, Pharmaceutical industry, Xenon, Medicine

Participants can register and access the webinar on the Investors section of Xenon’s website.

Key Points: 
  • Participants can register and access the webinar on the Investors section of Xenon’s website.
  • Sanjay J. Mathew, MD, Marjorie Bintliff Johnson and Raleigh White Johnson, Jr. Vice Chair for Research Professor of Psychiatry & Behavioral Sciences Menninger Department of Psychiatry & Behavioral Sciences at Baylor College of Medicine
    James W. Murrough, MD, PhD, Professor of Psychiatry and Neuroscience Director, Depression and Anxiety Center for Discovery and Treatment Icahn School of Medicine at Mount Sinai
    A live webcast of the company presentation will be available on the “ Investors ” section of Xenon's website and posted for replay following the event.
  • The above listed dates and times are subject to change.

Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board

Retrieved on: 
Tuesday, September 12, 2023
Memory, American Board of Psychiatry and Neurology, Central nervous system, University, Therapy, Sabbagh, Baylor University, Rett syndrome, Coronavirus Scientific Advisory Board, American Academy, University of Arizona College of Medicine – Phoenix, Doctor of Philosophy, CNS, Barrow Neurological Institute, American Board of Commissioners for Foreign Missions, DSM-IV codes, Journal, MD, Patient, Psychiatry, Baylor College of Medicine, Diagnosis, Research, American Academy of Neurology, Pharmaceutical industry, Dementia, Neurology

Prof. Dr. Marwan Sabbagh, MD, is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program at Barrow Neurological Institute.

Key Points: 
  • Prof. Dr. Marwan Sabbagh, MD, is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program at Barrow Neurological Institute.
  • He is also a professor and the Vice Chair of Research in the Institute’s Department of Neurology.
  • He is board certified in neurology by the American Board of Psychiatry and Neurology.
  • “I’m excited to join Anavex’s Scientific Advisory Board at this time of important progress of the Company,” said Professor Dr. Sabbagh.

Mersana Therapeutics Announces Changes in Leadership

Retrieved on: 
Wednesday, September 6, 2023
Docetaxel, GSK plc, University, Senior, Information technology, MRSN, Controller, Culture, Pharmacovigilance, Trastuzumab, Cancer, Assistant, Merck & Co., Retirement, Acquisition, Patient, Rhône-Poulenc, CFO, Baylor College of Medicine, ADC, Knowledge, Spacecraft, Pembrolizumab, Therapy, Management

“On behalf of the Board of Directors and the entire organization, I would like to express our sincere appreciation for Anna’s leadership of Mersana over the past eight years.

Key Points: 
  • “On behalf of the Board of Directors and the entire organization, I would like to express our sincere appreciation for Anna’s leadership of Mersana over the past eight years.
  • Martin Huber, M.D., has been named President and Chief Executive Officer of Mersana Therapeutics, Inc., effective September 11, 2023.
  • In conjunction with these changes, Chief Medical Officer Arvin Yang, M.D., and Chief People Officer Carla Poulson will be departing Mersana, effective September 29, 2023.
  • I want to express our sincere thanks to Arvin and Carla for their commitment and significant contributions to Mersana.

The Inner Circle Acknowledges, James C. Lasker as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Hematology-Oncology

Retrieved on: 
Tuesday, September 5, 2023
Lymphoma, Emory University, Yale University, Medical school, Physician, Education, Internal medicine, Friends, Temple University, Hematology, American Board of Internal Medicine, ABIM, American Society of Clinical Oncology, Baylor University, Cancer, Haemophilia, Prognosis, Partner (business rank), Mentorship, American Society of Hematology, Inner circle, Oncology, Baptists, American Board of Commissioners for Foreign Missions, Iron-deficiency anemia, Patient, Blood, School, BPA, Fellow, MD Anderson Cancer Center, California Community College Athletic Association, Anti-transglutaminase antibodies, Baylor College of Medicine, Diagnosis, Leukemia, American Society of Pediatric Hematology/Oncology, Society, Dentistry, Nursing, MD, Princeton University, Biology, Medicine

VERO BEACH, Fla., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James C. Lasker is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Hematology-Oncology.

Key Points: 
  • VERO BEACH, Fla., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James C. Lasker is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Hematology-Oncology.
  • Dr. Lasker pursued higher education at Yale University where he earned a Bachelor of Science degree in Biology.
  • He also noted that oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
  • The doctor would like to dedicate this honor to his mentors, Monty Lane, MD; Ken Walker, MD; and Jimmie Harvey, MD.

Globally Recognized Expert in Rare Neurologic Diseases, Dr. Michael Levy, Joins Trethera Scientific Advisory Board

Retrieved on: 
Tuesday, September 5, 2023
Demyelinating disease, DSM-IV codes, Optic neuritis, Central nervous system, University, Johns Hopkins Hospital, Myelin, Spinal cord, Cancer, Coronavirus Scientific Advisory Board, American Academy, Brain, Inflammation, Multiple sclerosis, Doctor of Philosophy, Associate, MS, Harvard Medical School, Nerve, CNS demyelinating autoimmune diseases, Patient, Division, Optic nerve, ADEM, Baylor College of Medicine, Hospital, Massachusetts General Hospital, American Academy of Neurology, Acute disseminated encephalomyelitis, Peripheral nervous system, Pharmaceutical industry, Philosophy, MD, Neurology

Dr. Levy will have a particular focus on evaluating the clinical development of Trethera’s lead asset, TRE-515, in demyelinating autoimmune diseases.

Key Points: 
  • Dr. Levy will have a particular focus on evaluating the clinical development of Trethera’s lead asset, TRE-515, in demyelinating autoimmune diseases.
  • When the myelin sheath is damaged, nerve impulses slow or even stop, causing neurological problems.
  • “We are honored to have Dr. Levy join our advisory board,” said Dr. Ken Schultz, Chairman and CEO of Trethera.
  • “He is a leading authority on rare neurologic autoimmune diseases and has expertise in both early and late-stage clinical trials.

Perimeter Medical Imaging AI Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 29, 2023
Mayo Clinic, Certified Management Accountant, Surgeon, CMA, Meta, University, International, International Accounting Standards Committee, Classification, Baylor College of Medicine, London Business School, Principal investigator, Clinical trial, Baylor University, Perimeter, Master, Sloan Fellows, FSE, Management science, ID, InterAction Council of Former Heads of State and Government, Baptists, Patient, International Financial Reporting Standards, Engineering, OCT, OTC, Webcast, CFO, Association of British HealthTech Industries, IAS, FDA, PINK, Medtech, International Accounting Standards Board, Management, Medical device, Cryptocurrency, DALLAS, Science

TORONTO and DALLAS, Aug. 29, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today reported financial results for its second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • TORONTO and DALLAS, Aug. 29, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today reported financial results for its second quarter ended June 30, 2023 and provided a corporate update.
  • In addition, I am pleased to report that Sara Brien will become Perimeter's Chief Financial Officer, effective September 1, 2023.
  • The study is evaluating the use of Perimeter B-Series OCT combined with its proprietary ImgAssist AI software during breast conservation surgery.
  • The Company will host a conference call and live audio webcast today, Tuesday, August 29, 2023, at 5:00 pm Eastern Time to discuss its second quarter 2023 results and to provide a corporate update.

Pacific Dermatology Specialists Announces New Fullerton, CA Location

Retrieved on: 
Friday, August 25, 2023
Salma, Society, Evidence-based medicine, Skin care, PPO, HMO, Dermatology, Baylor University, Multimedia, Human, Medicare, Suite, Patient, Baylor College of Medicine, UCLA, Nursing, Science

FULLERTON, Calif., August 25th, 2023 /PRNewswire-PRWeb/ -- Pacific Dermatology Specialists is proud to announce the opening of our newest location in Fullerton, CA.

Key Points: 
  • Pacific Dermatology Specialists is proud to announce the opening of our newest location in Fullerton, CA.
  • The practice offers a range of skin care services, including medical and pediatric dermatology.
  • FULLERTON, Calif., August 25th, 2023 /PRNewswire-PRWeb/ -- Pacific Dermatology Specialists is proud to announce the opening of our newest location in Fullerton, CA.
  • At Pacific Dermatology Specialists, they understand that receiving timely care is important, which is why they offer same-day and next-day appointments.

Crystal S. Denlinger, MD, FACP, Named New CEO of National Comprehensive Cancer Network; Robert W. Carlson, MD, Retiring After 10+ Years Leading Global Oncology Nonprofit

Retrieved on: 
Wednesday, August 23, 2023
University of Texas Southwestern Medical Center, Senior, American Society of Clinical Oncology, Health equity, Associate, Teaching hospital, NCCN, American College of Physicians, Cancer, Patient, American College, Chair, The College of New Jersey, BS, FRCP, Physician, FACP, Policy, National Comprehensive Cancer Network, Research, Organization, Panel, Mount Sinai Medical Center, Baylor College of Medicine, Caregiver, Abstract, Harold, Associate professor, Capitol Hill, Medicine, ORP, Journal of the National Comprehensive Cancer Network, New Jersey Medical School, Equitable, Regius Professor, Bone, ASCO, Society, Medical device, Nursing, MD

PLYMOUTH MEETING, Pa., Aug. 23, 2023 /PRNewswire/ -- Today the National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading academic cancer centers—announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO). Dr. Denlinger—who is currently NCCN's Senior Vice President, Chief Scientific Officer—is being promoted to lead the global guidelines organization following a national search to replace the retiring longtime CEO, Robert W. Carlson, MD.

Key Points: 
  • PLYMOUTH MEETING, Pa., Aug. 23, 2023 /PRNewswire/ -- Today the National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading academic cancer centers—announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO).
  • Crystal S. Denlinger, MD, FACP, to lead the National Comprehensive Cancer Network (NCCN), a global cancer nonprofit.
  • She will also lead and oversee programs advancing global collaborations, new oncology research, peer-reviewed publication, patient information, and cancer policy.
  • NCCN's recognition and influence relating to national and global cancer care policy also increased dramatically during his tenure."

Crystal S. Denlinger, MD, FACP, Named New CEO of National Comprehensive Cancer Network; Robert W. Carlson, MD, Retiring After 10+ Years Leading Global Oncology Nonprofit

Retrieved on: 
Wednesday, August 23, 2023
University of Texas Southwestern Medical Center, Senior, American Society of Clinical Oncology, Health equity, Associate, Teaching hospital, NCCN, American College of Physicians, Cancer, Patient, American College, Chair, The College of New Jersey, BS, FRCP, Physician, FACP, Policy, National Comprehensive Cancer Network, Research, Organization, Panel, Mount Sinai Medical Center, Baylor College of Medicine, Caregiver, Abstract, Harold, Associate professor, Capitol Hill, Medicine, ORP, Journal of the National Comprehensive Cancer Network, New Jersey Medical School, Equitable, Regius Professor, Bone, ASCO, Society, Medical device, Nursing, MD

PLYMOUTH MEETING, Pa., Aug. 23, 2023 /PRNewswire/ -- Today the National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading academic cancer centers—announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO). Dr. Denlinger—who is currently NCCN's Senior Vice President, Chief Scientific Officer—is being promoted to lead the global guidelines organization following a national search to replace the retiring longtime CEO, Robert W. Carlson, MD.

Key Points: 
  • PLYMOUTH MEETING, Pa., Aug. 23, 2023 /PRNewswire/ -- Today the National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading academic cancer centers—announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO).
  • Dr. Denlinger has a long history of global cancer care leadership with NCCN and beyond.
  • She will also lead and oversee programs advancing global collaborations, new oncology research, peer-reviewed publication, patient information, and cancer policy.
  • NCCN's recognition and influence relating to national and global cancer care policy also increased dramatically during his tenure."